Osimertinib combined with bevacizumab as the first‐line treatment in non‐small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations

Osimertinib combined with bevacizumab as the first‐line treatment in non‐small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations

Abstract Background The efficacy and safety of osimertinib combined with bevacizumab in non‐small cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor receptor (EGFR) mutations have not been fully studied. Methods Treatment‐naïve NSCLC patients with brain metasta...

Full description

Bibliographic Details
Main Authors: Ling Zhang, Yunhong You, Xueli Liu, Fengjuan Liu, Keke Nie, Youxin Ji
Format: Article
Language:English
Published: Wiley 2023-05-01
Series:Thoracic Cancer
Subjects:
brain metastasis
epidermal growth factor receptor tyrosine kinase inhibitor
non‐small cell lung cancer
osimertinib
target therapy
Online Access:https://doi.org/10.1111/1759-7714.14880

Internet

https://doi.org/10.1111/1759-7714.14880

Similar Items